English articles
- BeOne Bets on Four RAS Drugs: The Real Asset Is Development Optionality
- Moderna Surges 176.97% After Its Personalized Cancer Vaccine Clears a Phase 3 Test
- NVIDIA Enters Pharma: BMS Readies 576 GPUs as Lilly Commits Up to $1 Billion
- Just $74 Million Short: Can Skyrizi Succeed Humira as the Autoimmune Drug King?
- Eli Lilly Sold $23 Billion in One Quarter. Why Is It Still Rushing to Buy the Next Drug King?
- Revenue Jumped 39%, Yet Iovance Still Lost $47 Million: Can Cancer Cell Therapy Become a Business?
- Pfizer Paid Billions for Obesity Assets. Is It Already Cutting Its Losses?
- GSK's US$2 Billion Cough-Drug Bet Hit a Phase 3 Reproducibility Wall
- This Taiwanese Biotech Is Building a Nanorocket Inside the Human Body
- Novo Nordisk’s 6,300-Patient ZEUS Failure: A Textbook Lesson in Translational Risk
- Can $1.2 Billion Help AI Double the Pace of Drug R&D?
- After 20 Years, Have HDAC Inhibitors Finally Found Their Role? Why ABT-301 Could Become a Next-Generation Combination Backbone
- $130 Billion in Six Months: Big Pharma Is Buying Time
- J&J's Oral Psoriasis Drug Logged 18,000 Prescriptions in Its First Full Quarter. Is It Coming for Injectables?
- Why These Four Biotechs Can Afford Not to Sell
- $2.2 Billion for the Next Autoimmune Blockbuster?
- Investors, Take Note: Hair Loss Could Be Biotech's Next Weight-Loss-Drug-Sized Blockbuster
- More Than $1 Billion in One Quarter: Why Did Alnylam Plunge 28%?
- A $400 Billion Pharma Merger? AstraZeneca and Bristol Myers Squibb Are Reportedly Talking
- Tau Earned a Retest: Why Biogen Is Taking Diranersen Into Phase 3 After CELIA Missed Its Primary Endpoint
- Bempikibart in Alopecia Areata: A 33-Patient Signal Is Not Yet a Win Over JAK Inhibitors
- AnBogen Therapeutics: Building a “Starlink” for Cancer Immunotherapy
- After Xtandi: Can Astellas Build an Oncology Platform?
- Pelacarsen's HORIZON Test: Does Lowering Lp(a) Prevent Cardiovascular Events?
- T-cell Exhaustion Across PD-1, CAR-T and TCE: Immunotherapy's Next Contest Is Durability
- $130 Billion in Six Months: Big Pharma Is Buying Time
- Roche's Hidden Succession Engine: How 19 New Molecules Could Power the Next Growth Cycle
- When a Biotech Says No to a Sale: Five Tests of Whether It Can Become a Biopharma
- SpaceX Goes to Orbit. Is the Money in the Crystals?
- Madrigal's MASH Platform Strategy: Rezdiffra as the Cornerstone, siRNA as the Next Growth Engine
